Lineage Cell Therapeutics, Inc. (LCTX)

Market Cap	209.27M
Revenue (ttm)	8.95M
Net Income (ttm)	-21.49M
Shares Out	188.53M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	330,657
Open	1.100
Previous Close	1.100
Day's Range	1.100 - 1.140
52-Week Range	0.840 - 1.610
Beta	1.33
Analysts	Strong Buy
Price Target	6.50 (+485.59%)
Earnings Date	May 9, 2024

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 68
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: LCTX

Financial Performance

In 2023, LCTX's revenue was $8.95 million, a decrease of -39.16% compared to the previous year's $14.70 million. Losses were -$21.49 million, -18.22% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for LCTX stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 485.59% from the latest price.

Price Target

$6.5

(485.59% upside)

Analyst Consensus: Strong Buy